Consumption of excessive sodium is a direct cause of hypertension, which affects nearly 1 in 3 Americans. CDC’s next Public Health Grand Rounds, entitled Sodium Reduction: Time for Choice, will be webcast live from CDC headquarters in Atlanta, Georgia on Thursday, April 21st at 1 p.m. (EDT) at www.cdc.gov/about/grand-rounds. Dr. Darwin Labarthe, Director of CDC’s Heart Disease and Stroke Prevention Division, will lead a discussion with other experts on the consequences of too much sodium in the diet and the regulatory and technological context for the use of salt in our food supply. The session will also review current sodium control efforts such as the National Salt Reduction Initiative and food procurement policies, and separate fact from fiction to support actions needed to address this very real public health burden.
Controlling the amount of sodium is not as simple as removing salt shakers from tables. Much of the sodium in food comes from processing and restaurant use. A multi-pronged strategy is needed to address the health consequences of excessive sodium. Tune in to the CDC webcast to learn the facts and options for addressing this critical issue.
Showing posts with label stroke. Show all posts
Showing posts with label stroke. Show all posts
Friday, 15 April 2011
Friday, 30 April 2010
National Forum for Heart Disease and Stroke Prevention
On Monday and Tuesday the National Forum for Heart Disease and Stroke Prevention held its 8th annual meeting in Washington DC. The meeting focused on developing the will to prevent heart disease and stroke in the public and private sectors, including drawing attention to the recently released Institute of Medicine (IOM) reports on hypertension and sodium reduction.
Dr. David Fleming, the chair of the IOM Committee on Strategies to Reduce Sodium Intake and a member of Partnership for Prevention’s National Commission on Prevention Priorities (NCPP), presented information about actions that can be taken by food manufacturers, the federal government, and public health professionals to reduce the sodium content in foods. The sodium plenary session was timely, occurring a few days after Partnership’s congressional briefing on reducing sodium consumption.
Another highlight from the meeting was a session on connecting traditional and emerging communication approaches to change behavior. Dr. Rob Gould, President and CEO of Partnership, spoke about behavior change and exciting new methods of communication. Other panelists hailed from the CDC, NIH, and Pew Research Center.
The National Forum on Heart Disease and Stroke Prevention works to provide leadership and facilitate collaboration among those committed to preventing heart disease and stroke. Partnership participated in last year’s Forum Symposium on the Health Economics of Cardiovascular Disease, and recently joined as a Forum member. Partnership’s work in cardiovascular disease prevention includes its Aspirin Task Force , a multidisciplinary group of medical professionals committed to promoting aspirin for primary prevention of heart disease and stroke, as well as projects in its priority areas of tobacco cessation and control, and poor nutrition and physical inactivity (obesity). For more information on the Forum and the Annual Meeting, please click here.
Rebecca Doigan
Program Associate
Partnership for Prevention
Dr. David Fleming, the chair of the IOM Committee on Strategies to Reduce Sodium Intake and a member of Partnership for Prevention’s National Commission on Prevention Priorities (NCPP), presented information about actions that can be taken by food manufacturers, the federal government, and public health professionals to reduce the sodium content in foods. The sodium plenary session was timely, occurring a few days after Partnership’s congressional briefing on reducing sodium consumption.
Another highlight from the meeting was a session on connecting traditional and emerging communication approaches to change behavior. Dr. Rob Gould, President and CEO of Partnership, spoke about behavior change and exciting new methods of communication. Other panelists hailed from the CDC, NIH, and Pew Research Center.
The National Forum on Heart Disease and Stroke Prevention works to provide leadership and facilitate collaboration among those committed to preventing heart disease and stroke. Partnership participated in last year’s Forum Symposium on the Health Economics of Cardiovascular Disease, and recently joined as a Forum member. Partnership’s work in cardiovascular disease prevention includes its Aspirin Task Force , a multidisciplinary group of medical professionals committed to promoting aspirin for primary prevention of heart disease and stroke, as well as projects in its priority areas of tobacco cessation and control, and poor nutrition and physical inactivity (obesity). For more information on the Forum and the Annual Meeting, please click here.
Rebecca Doigan
Program Associate
Partnership for Prevention
Friday, 5 March 2010
Aspirin Use in Asymptomatic Patients
Earlier this week, the research article, “Aspirin for Prevention of Cardiovascular Events in a General Population Screened for a Low Ankle Brachial Index (ABI)”, was published in JAMA. The goal of the study was to determine if daily aspirin reduced the risk of heart attack and stroke in patients with a low ABI, a quick and inexpensive way to establish risk for these events, and no other risk factors. Researchers hoped to show that the ABI could identify asymptomatic higher risk individuals that could benefit from preventive treatments, such as aspirin use.
The researchers found that aspirin was not effective in preventing first heart attack, stroke, or other cardiovascular events for individuals with low ABI and an absence of other risk factors. However, due to the fact that ABI was the only indicator used when determining risk, the study population was ultimately found to be at very low risk for heart attack and stroke. According to current guidelines, this low risk group would not be encouraged to use aspirin. So the study may actually say more about ABI or the range of ABI as a screening tool for cardiovascular risk than aspirin for primary prevention of cardiovascular events.
Other issues with the study include adherence to the therapy and disproportionate number of females in the study. Interestingly, the study showed no statistically significant difference between the aspirin and control groups for bleeding. Recently, aspirin use for primary prevention has been questioned due to a potential increased risk for gastrointestinal and intracranial bleeding; this study shows that bleeding events were similar between aspirin and non-aspirin users.
Ultimately, this study shows that ABI or the ABI threshold measurement used (0.95) is not enough to predict higher risk of heart attack and stroke on a population level. Future studies with more participants, improved compliance rates, a more equitable distribution of males and females, and a lower level of ABI for study inclusion are necessary to shed more light on this issue. An editorial, also published in JAMA, further explains the potential limitations of the study. Although at first glance this article appears to be another critique on aspirin for primary prevention-as many media outlets suggested- the current American Heart Association and United States Preventive Services Task Force guidelines for aspirin use to prevent first heart attacks and strokes should still be followed. And, as they recommend, those considering aspirin should talk to their health care provider to determine if aspirin is right for them.
Posted by:
Rebecca Doigan
Program Associate, Partnership for Prevention
The researchers found that aspirin was not effective in preventing first heart attack, stroke, or other cardiovascular events for individuals with low ABI and an absence of other risk factors. However, due to the fact that ABI was the only indicator used when determining risk, the study population was ultimately found to be at very low risk for heart attack and stroke. According to current guidelines, this low risk group would not be encouraged to use aspirin. So the study may actually say more about ABI or the range of ABI as a screening tool for cardiovascular risk than aspirin for primary prevention of cardiovascular events.
Other issues with the study include adherence to the therapy and disproportionate number of females in the study. Interestingly, the study showed no statistically significant difference between the aspirin and control groups for bleeding. Recently, aspirin use for primary prevention has been questioned due to a potential increased risk for gastrointestinal and intracranial bleeding; this study shows that bleeding events were similar between aspirin and non-aspirin users.
Ultimately, this study shows that ABI or the ABI threshold measurement used (0.95) is not enough to predict higher risk of heart attack and stroke on a population level. Future studies with more participants, improved compliance rates, a more equitable distribution of males and females, and a lower level of ABI for study inclusion are necessary to shed more light on this issue. An editorial, also published in JAMA, further explains the potential limitations of the study. Although at first glance this article appears to be another critique on aspirin for primary prevention-as many media outlets suggested- the current American Heart Association and United States Preventive Services Task Force guidelines for aspirin use to prevent first heart attacks and strokes should still be followed. And, as they recommend, those considering aspirin should talk to their health care provider to determine if aspirin is right for them.
Posted by:
Rebecca Doigan
Program Associate, Partnership for Prevention
Subscribe to:
Posts (Atom)